Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 2004, p. 4226-4233, Vol. 48, No. 11
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.11.4226-4233.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Hypermutation and the Preexistence of Antibiotic-Resistant Pseudomonas aeruginosa Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections
Antonio Oliver,1*
Bruce R. Levin,2
Carlos Juan,1
Fernando Baquero,3 and
Jesús Blázquez4
Servicio de Microbiología, Hospital Son Dureta, Palma de Mallorca,1
Servicio de Microbiología, Hospital Ramón y Cajal,3
Departamento de Biotecnología Microbiana, Centro Nacional de Biotecnología-CSIC, Madrid, Spain,4
Department of Biology, Emory University, Atlanta, Georgia2
Received 16 March 2004/
Returned for modification 18 June 2004/
Accepted 5 July 2004
Whether or not resistant mutants will be present before the start of antibiotic treatment of an initially susceptible population of bacteria depends on the size of the infecting population, the rate of mutation to resistance, and the amount of time that the population has been maintained. In the present investigation, we argue that for the treatment of chronic infections caused by hypermutable Pseudomonas aeruginosa of the sort frequently found in cystic fibrosis patients, mutants resistant to all single antipseudomonal drugs will almost invariably be present in a high proportion at the onset of treatment, and consequently, these strains should be considered resistant to all agents when they are used as monotherapy. Using a construct of P. aeruginosa strain PAO1 with a mutS deletion (strain PAO
mutS), we show that when in vitro populations of less than 5 x 104 seemingly susceptible hypermutable bacteria are confronted with any of 11 antipseudomonal agents, mutants for which the MICs and the minimum bactericidal concentrations are in the range of clinical resistance will almost invariably ascend to dominance within 24 to 36 h. This does not occur for PAO1 without the mutS deletion. The results of our detailed analysis of this evolution of acquired resistance to two of these antibiotics, imipenem and ciprofloxacin, indicate that although the rates of mutation to resistance in PAO
mutS are on the order of 1 x 106 per generation, resistant mutants are very likely to either be present in cultures of between 2 x 104 and 4 x 104 bacteria or arise after the bacterial populations are confronted with antibiotics. We also demonstrate with in vitro experiments that the problem of acquired resistance to treatment with single antibiotics can be thwarted by combination therapy with pairs of antibiotics of different classes with synergistic activities. We discuss the clinical implications of our analysis of these observations.
* Corresponding author. Mailing address: Servicio de Microbiología, Hospital Son Dureta, C. Andrea Doria N° 55, 07014 Palma de Mallorca, Spain. Phone: 34 971 175 185. Fax: 34 971 175 185. E-mail:
aoliver{at}hsd.es.
Antimicrobial Agents and Chemotherapy, November 2004, p. 4226-4233, Vol. 48, No. 11
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.11.4226-4233.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Castaneda-Garcia, A., Rodriguez-Rojas, A., Guelfo, J. R., Blazquez, J.
(2009). The Glycerol-3-Phosphate Permease GlpT Is the Only Fosfomycin Transporter in Pseudomonas aeruginosa. J. Bacteriol.
191: 6968-6974
[Abstract]
[Full Text]
-
Mulet, X., Macia, M. D., Mena, A., Juan, C., Perez, J. L., Oliver, A.
(2009). Azithromycin in Pseudomonas aeruginosa Biofilms: Bactericidal Activity and Selection of nfxB Mutants. Antimicrob. Agents Chemother.
53: 1552-1560
[Abstract]
[Full Text]
-
Rodriguez-Rojas, A., Blazquez, J.
(2009). The Pseudomonas aeruginosa pfpI Gene Plays an Antimutator Role and Provides General Stress Protection. J. Bacteriol.
191: 844-850
[Abstract]
[Full Text]
-
Mena, A., Smith, E. E., Burns, J. L., Speert, D. P., Moskowitz, S. M., Perez, J. L., Oliver, A.
(2008). Genetic Adaptation of Pseudomonas aeruginosa to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation. J. Bacteriol.
190: 7910-7917
[Abstract]
[Full Text]
-
Wiegand, I., Marr, A. K., Breidenstein, E. B. M., Schurek, K. N., Taylor, P., Hancock, R. E. W.
(2008). Mutator Genes Giving Rise to Decreased Antibiotic Susceptibility in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
52: 3810-3813
[Abstract]
[Full Text]
-
Waine, D. J., Honeybourne, D., Smith, E. G., Whitehouse, J. L., Dowson, C. G.
(2008). Association between Hypermutator Phenotype, Clinical Variables, Mucoid Phenotype, and Antimicrobial Resistance in Pseudomonas aeruginosa. J. Clin. Microbiol.
46: 3491-3493
[Abstract]
[Full Text]
-
Lutter, E. I., Faria, M. M. P., Rabin, H. R., Storey, D. G.
(2008). Pseudomonas aeruginosa Cystic Fibrosis Isolates from Individual Patients Demonstrate a Range of Levels of Lethality in Two Drosophila melanogaster Infection Models. Infect. Immun.
76: 1877-1888
[Abstract]
[Full Text]
-
Pope, C. F., O'Sullivan, D. M., McHugh, T. D., Gillespie, S. H.
(2008). A Practical Guide to Measuring Mutation Rates in Antibiotic Resistance. Antimicrob. Agents Chemother.
52: 1209-1214
[Full Text]
-
Macia, M. D., Mena, A., Borrell, N., Perez, J. L., Oliver, A.
(2007). Increased Susceptibility to Colistin in Hypermutable Pseudomonas aeruginosa Strains from Chronic Respiratory Infections. Antimicrob. Agents Chemother.
51: 4531-4532
[Full Text]
-
Henrichfreise, B., Wiegand, I., Pfister, W., Wiedemann, B.
(2007). Resistance Mechanisms of Multiresistant Pseudomonas aeruginosa Strains from Germany and Correlation with Hypermutation. Antimicrob. Agents Chemother.
51: 4062-4070
[Abstract]
[Full Text]
-
Kirov, S. M., Webb, J. S., O'May, C. Y., Reid, D. W., Woo, J. K. K., Rice, S. A., Kjelleberg, S.
(2007). Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology
153: 3264-3274
[Abstract]
[Full Text]
-
Henrichfreise, B., Wiegand, I., Luhmer-Becker, I., Wiedemann, B.
(2007). Development of Resistance in Wild-Type and Hypermutable Pseudomonas aeruginosa Strains Exposed to Clinical Pharmacokinetic Profiles of Meropenem and Ceftazidime Simulated In Vitro. Antimicrob. Agents Chemother.
51: 3642-3649
[Abstract]
[Full Text]
-
Moir, D. T., Ming Di, , Opperman, T., Schweizer, H. P., Bowlin, T. L.
(2007). A High-Throughput, Homogeneous, Bioluminescent Assay for Pseudomonas aeruginosa Gyrase Inhibitors and Other DNA-Damaging Agents. J Biomol Screen
12: 855-864
[Abstract]
-
Plasencia, V., Borrell, N., Macia, M. D., Moya, B., Perez, J. L., Oliver, A.
(2007). Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents. Antimicrob. Agents Chemother.
51: 2574-2581
[Abstract]
[Full Text]
-
Kenna, D. T., Doherty, C. J., Foweraker, J., Macaskill, L., Barcus, V. A., Govan, J. R. W.
(2007). Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis. Microbiology
153: 1852-1859
[Abstract]
[Full Text]
-
Harrison, F., Buckling, A.
(2007). High relatedness selects against hypermutability in bacterial metapopulations. Proc R Soc B
274: 1341-1347
[Abstract]
[Full Text]
-
Montanari, S., Oliver, A., Salerno, P., Mena, A., Bertoni, G., Tummler, B., Cariani, L., Conese, M., Doring, G., Bragonzi, A.
(2007). Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology
153: 1445-1454
[Abstract]
[Full Text]
-
Mena, A., Macia, M. D., Borrell, N., Moya, B., de Francisco, T., Perez, J. L., Oliver, A.
(2007). Inactivation of the Mismatch Repair System in Pseudomonas aeruginosa Attenuates Virulence but Favors Persistence of Oropharyngeal Colonization in Cystic Fibrosis Mice. J. Bacteriol.
189: 3665-3668
[Abstract]
[Full Text]
-
Driffield, K. L., Bostock, J. M., Miller, K., O'Neill, A. J., Hobbs, J. K., Chopra, I.
(2006). Evolution of extended-spectrum {beta}-lactamases in a MutS-deficient Pseudomonas aeruginosa hypermutator. J Antimicrob Chemother
58: 905-907
[Full Text]
-
Macia, M. D., Borrell, N., Segura, M., Gomez, C., Perez, J. L., Oliver, A.
(2006). Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
50: 975-983
[Abstract]
[Full Text]
-
Cirz, R. T., Romesberg, F. E.
(2006). Induction and Inhibition of Ciprofloxacin Resistance-Conferring Mutations in Hypermutator Bacteria. Antimicrob. Agents Chemother.
50: 220-225
[Abstract]
[Full Text]
-
Morosini, M. I., Garcia-Castillo, M., Loza, E., Perez-Vazquez, M., Baquero, F., Canton, R.
(2005). Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips. J. Clin. Microbiol.
43: 4480-4485
[Abstract]
[Full Text]
-
Oldak, E., Trafny, E. A.
(2005). Secretion of Proteases by Pseudomonas aeruginosa Biofilms Exposed to Ciprofloxacin. Antimicrob. Agents Chemother.
49: 3281-3288
[Abstract]
[Full Text]
-
Macia, M. D., Blanquer, D., Togores, B., Sauleda, J., Perez, J. L., Oliver, A.
(2005). Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in Pseudomonas aeruginosa Strains Causing Chronic Lung Infections. Antimicrob. Agents Chemother.
49: 3382-3386
[Abstract]
[Full Text]
-
Ciofu, O., Riis, B., Pressler, T., Poulsen, H. E., Hoiby, N.
(2005). Occurrence of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Patients Is Associated with the Oxidative Stress Caused by Chronic Lung Inflammation. Antimicrob. Agents Chemother.
49: 2276-2282
[Abstract]
[Full Text]